$1.29 Billion is the total value of Casdin Capital, LLC's 46 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BLFS | BIOLIFE SOLUTIONS INC | $137,735,266 | -20.0% | 7,566,292 | 0.0% | 10.67% | -5.6% | |
| EQRX INC | $97,238,066 | -50.3% | 39,527,669 | 0.0% | 7.53% | -41.4% | ||
| ILMN | ILLUMINA INC | $77,847,000 | +6.0% | 385,000 | 0.0% | 6.03% | +25.0% | |
| SOMALOGIC INC | $31,636,730 | -13.4% | 12,604,275 | 0.0% | 2.45% | +2.1% | ||
| FATE | FATE THERAPEUTICS INC | $20,684,500 | -55.0% | 2,050,000 | 0.0% | 1.60% | -46.9% | |
| IPSC | CENTURY THERAPEUTICS INC | $16,448,729 | -48.1% | 3,206,380 | 0.0% | 1.27% | -38.8% | |
| BEAM | BEAM THERAPEUTICS INC | $14,470,700 | -17.9% | 370,000 | 0.0% | 1.12% | -3.2% | |
| NTLA | INTELLIA THERAPEUTICS INC | $10,292,550 | -37.7% | 295,000 | 0.0% | 0.80% | -26.5% | |
| ARVN | ARVINAS INC | $6,842,000 | -23.1% | 200,000 | 0.0% | 0.53% | -9.2% | |
| MRTX | MIRATI THERAPEUTICS INCcall | $4,531,000 | -35.1% | 100,000 | 0.0% | 0.35% | -23.5% | |
| SEMA4 HOLDINGS CORP | $4,336,213 | -69.9% | 16,437,500 | 0.0% | 0.34% | -64.5% | ||
| GLUE | MONTE ROSA THERAPEUTICS INC | $3,887,812 | -6.9% | 510,882 | 0.0% | 0.30% | +9.9% | |
| OMIC | SINGULAR GENOMICS SYSTEMS IN | $2,704,901 | -19.6% | 1,345,722 | 0.0% | 0.21% | -5.0% | |
| EXSCIENTIA PLCads | $1,140,087 | -35.1% | 213,900 | 0.0% | 0.09% | -23.5% | ||
| LIANBIOsponsored ads | $338,521 | -17.6% | 206,415 | 0.0% | 0.03% | -3.7% | ||
| KRON | KRONOS BIO INC | $200,619 | -51.7% | 123,839 | 0.0% | 0.02% | -40.7% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
| SC 13D/A | 2024-03-20 |
| 4 | 2024-03-06 |
| 4 | 2024-03-06 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.